- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02154659
The Difference of Reflux Pattern Between the Patients Who Have Postprandial Reflux Symptoms
March 14, 2019 updated by: Yonsei University
Gastroesophageal reflux disease is increasing worldwide.
The causes of reflux symptoms are not found exactly.
especially, the postprandial reflux symptoms are more common than the all day reflux symptoms.
One of the causes of reflux symptoms is the relaxation of the lower sphincter of the esophagus.
But, the sphincter relaxation also occur in normal people.
But, there is a difference in postprandial reflux pattens between the patients and the normal people.
So, in this study, we want to compare the difference of reflux pattern between the patients who have postprandial reflux symptoms and normal people though the 24hr pH monitoring.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
81
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Yonsei University College of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- over 19 years old, male and female
- normal people (control group, who has no postprandial reflux symptoms
- patients who have postprandial reflux symptoms (postprandial reflux symptom means that within the last 6 months, postprandial reflux symptoms more than once a week for more than 1 month)
Exclusion Criteria:
- patients who have nasoesophageal stricture
- patients who have bleeding tendency
- patients who have esophageal varix
- patients who have cardioverter implantation
- patients who had surgery for esophagus, stomach or duodenum
- patients who are taking medications, gastrointestinal motility drugs
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: postprandial reflux group
Esophageal pH monitoring is the current gold standard for diagnosis of gastroesophageal reflux disease.
It provides direct physiologic measurement of acid in the esophagus and is the most objective method to document reflux disease, assess the severity of the disease and monitor the reflux acidity.
|
|
Other: normal group
Esophageal pH monitoring is the current gold standard for diagnosis of gastroesophageal reflux disease.
It provides direct physiologic measurement of acid in the esophagus and is the most objective method to document reflux disease, assess the severity of the disease and monitor the reflux acidity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The difference of reflux pattern at postprandial period between the patients who have postprandial reflux symptoms and the normal people
Time Frame: Within the 24 hours after the 24hr pH monitoring
|
Primary Outcome - The difference of reflux pattern at postprandial period between the patients who have postprandial reflux symptoms and the normal people The postprandial reflux symptom means that the symptoms more than once for a week for more than 1 month
|
Within the 24 hours after the 24hr pH monitoring
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The difference of esophageal reflux pH between the patients who have postprandial reflux symptoms and the normal people
Time Frame: Within the 24 hours after the 24hr pH monitoring
|
Within the 24 hours after the 24hr pH monitoring
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2014
Primary Completion (Actual)
December 7, 2015
Study Completion (Actual)
December 7, 2015
Study Registration Dates
First Submitted
May 30, 2014
First Submitted That Met QC Criteria
May 30, 2014
First Posted (Estimate)
June 3, 2014
Study Record Updates
Last Update Posted (Actual)
March 18, 2019
Last Update Submitted That Met QC Criteria
March 14, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4-2013-0680
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroesophageal Reflux Disease
-
TakedaTerminatedGastroesophageal Reflux Disease | Non-erosive Reflux DiseaseSwitzerland, Netherlands
-
Vanderbilt University Medical CenterCompletedGastroesophageal Reflux Disease (GERD) | Non-erosive Reflux Disease (NERD)United States
-
Mansoura UniversityWithdrawnGastroesophageal Reflux Disease
-
Cliniques universitaires Saint-Luc- Université...UnknownGastroesophageal Reflux DiseaseBelgium
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
King Chulalongkorn Memorial HospitalCompleted
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroesophageal Reflux Disease | GERD | Acid Reflux | RefluxUnited States
-
PfizerTerminatedGastroesophageal Reflux DiseaseBrazil, Germany, Korea, Republic of, Belgium, Spain, Slovakia, France
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedGastroesophageal Reflux Disease (GERD) | RefluxUnited States, Canada
Clinical Trials on 24hr pH monitoring
-
Medtronic - MITGCompletedGastro Esophageal Reflux DiseaseIsrael
-
University Hospital OstravaCompletedNasal Polyps | Laryngopharyngeal Reflux | Nasal DiseasesCzech Republic
-
Vanderbilt UniversityTerminatedAspiration, RespiratoryUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Vanderbilt University Medical CenterTerminatedIdentify Normal MII-pH ParametersUnited States
-
Medtronic - MITGWithdrawnGastro Esophageal Reflux DiseaseIsrael
-
Asian Institute of Gastroenterology, IndiaRecruitingEsophageal Diseases | Esophagitis | Reflux DiseaseIndia
-
Hospices Civils de LyonRecruiting